hydroxyprostaglandin dehydrogenases

Summary

Summary: Catalyzes reversibly the oxidation of hydroxyl groups of prostaglandins.

Top Publications

  1. ncbi Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
    Michael Stanbrough
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 66:2815-25. 2006
  2. ncbi β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells
    Helena J M Smartt
    Cancer Research UK Colorectal Tumour Biology Research Group, School of Cellular and Molecular Medicine, University Walk, University of Bristol, Bristol, UK
    Gut 61:1306-14. 2012
  3. ncbi Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer
    Johannes Hofland
    Departments of Internal Medicine, Urology, and Pathology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Cancer Res 70:1256-64. 2010
  4. ncbi Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk
    Bernd Frank
    Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
    Carcinogenesis 32:190-6. 2011
  5. pmc 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer
    Michael G Backlund
    Department of Medicine, Cell and Developmental Biology, Vanderbilt University Medical Center and the Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6838, USA
    J Biol Chem 280:3217-23. 2005
  6. pmc Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2
    Kyu Lim
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Mol Cancer Ther 8:3046-55. 2009
  7. ncbi Prostaglandin catabolic enzymes as tumor suppressors
    Hsin Hsiung Tai
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA
    Cancer Metastasis Rev 30:409-17. 2011
  8. pmc Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
    Michael C Byrns
    Center of Excellence in Environmental Toxicology, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
    J Steroid Biochem Mol Biol 130:7-15. 2012
  9. pmc Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs
    Michael C Byrns
    Department of Pharmacology, Center of Excellence in Environmental Toxicology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6084, United States
    Chem Biol Interact 178:221-7. 2009
  10. ncbi Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer
    Tina Smuc
    Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
    Mol Cell Endocrinol 301:74-82. 2009

Research Grants

Detail Information

Publications202 found, 100 shown here

  1. ncbi Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
    Michael Stanbrough
    Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 66:2815-25. 2006
    ..These results indicate that enhanced intracellular conversion of adrenal androgens to testosterone and dihydrotestosterone is a mechanism by which prostate cancer cells adapt to androgen deprivation and suggest new therapeutic targets...
  2. ncbi β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells
    Helena J M Smartt
    Cancer Research UK Colorectal Tumour Biology Research Group, School of Cellular and Molecular Medicine, University Walk, University of Bristol, Bristol, UK
    Gut 61:1306-14. 2012
    ..As Wnt/β-catenin signalling is also deregulated early in colorectal neoplasia, a study was undertaken to determine whether β-catenin represses 15-PGDH expression...
  3. ncbi Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer
    Johannes Hofland
    Departments of Internal Medicine, Urology, and Pathology, Erasmus MC, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Cancer Res 70:1256-64. 2010
    ....
  4. ncbi Association of hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD) variants and colorectal cancer risk
    Bernd Frank
    Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
    Carcinogenesis 32:190-6. 2011
    ..82, 95% CI = 0.70, 0.95, P = 0.01) as well as among smokers (OR = 0.74, 95% CI = 0.61, 0.90, P = 0.003). Yet, our data do not support the previously reported associations of HPGD tagSNPs and risk of CRC...
  5. pmc 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer
    Michael G Backlund
    Department of Medicine, Cell and Developmental Biology, Vanderbilt University Medical Center and the Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6838, USA
    J Biol Chem 280:3217-23. 2005
    ..In summary, these results suggest a novel tumor suppressive role for 15-PGDH due to loss of expression during colorectal tumor progression...
  6. pmc Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2
    Kyu Lim
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Mol Cancer Ther 8:3046-55. 2009
    ..These findings provide important preclinical evidence and molecular insight for utilization of omega-3 PUFAs for the chemoprevention and treatment of human HCC...
  7. ncbi Prostaglandin catabolic enzymes as tumor suppressors
    Hsin Hsiung Tai
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA
    Cancer Metastasis Rev 30:409-17. 2011
    ..Future directions of research on these prostaglandin catabolic enzymes as tumor suppressors are also discussed...
  8. pmc Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride
    Michael C Byrns
    Center of Excellence in Environmental Toxicology, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States
    J Steroid Biochem Mol Biol 130:7-15. 2012
    ..Treatment options in prostate cancer that target 5α-reductase where AKR1C3 co-exists may be less effective due to the diversion of Δ(4)-Adione to testosterone...
  9. pmc Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs
    Michael C Byrns
    Department of Pharmacology, Center of Excellence in Environmental Toxicology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6084, United States
    Chem Biol Interact 178:221-7. 2009
    ..Both strategies are informed by crystal structures of ternary AKR1C3.NADP(+).NSAID complexes. The identification of NSAID analogs as specific inhibitors of AKR1C3 will help validate its role in the proliferation of breast cancer cells...
  10. ncbi Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer
    Tina Smuc
    Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
    Mol Cell Endocrinol 301:74-82. 2009
    ..Up-regulation of AKR1C1 and AKR1C3 can result in lower levels of the protective progesterone, which acts mainly via PR-B...
  11. ncbi Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer
    Li Yang
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Cancer Res 67:5587-93. 2007
    ..This effect is reversible in a subset of NSCLC upon treatment with an EGFR TKI...
  12. ncbi 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer
    Ido Wolf
    Division of Hematology Oncology, Cedars Sinai Medical Center, University of California at Los Angeles School of Medicine, Los Angeles, CA 90048, USA
    Cancer Res 66:7818-23. 2006
    ..Our results indicate for the first time that 15-PGDH may be a novel tumor suppressor gene in breast cancer, and suggest that this enzyme can modulate the ER pathway...
  13. pmc 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis
    Seung Jae Myung
    Department of Medicine, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Proc Natl Acad Sci U S A 103:12098-102. 2006
    ....
  14. ncbi Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer
    K Wako
    Division of Urology, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    J Clin Pathol 61:448-54. 2008
    ..The association between the expression of androgen receptor (AR) or androgen-converting enzymes and malignant potential in prostate cancer (PCa) was examined...
  15. pmc Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors
    Hung Pham
    Department of Medicine, Hirshberg Laboratories for Pancreatic Cancer Research, and David Geffen School of Medicine, University of California, Los Angeles, CA 90095 1786, USA
    Pancreas 39:332-9. 2010
    ..Down-regulation of PGDH contributes to PGE2 accumulation in lung and colon cancers but has not been identified in pancreatic cancer...
  16. ncbi cDNA cloning, expression and characterization of human prostaglandin F synthase
    T Suzuki-Yamamoto
    Department of Anatomy and Cell Biology, School of Medicine, The University of Tokushima, Kuramoto, Japan
    FEBS Lett 462:335-40. 1999
    ..These results support the notion that human PGFS plays an important role in the pathogenesis of allergic diseases such as asthma...
  17. ncbi Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase
    Naoki Wakimoto
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, USA
    Cancer Res 68:6978-86. 2008
    ..Our studies provide evidence that the up-regulation of 15-PGDH induced by NSAIDs has the potential to inhibit growth of GBM, in part, by up-regulation of p21 possibly independent from COX-2 enzymatic function...
  18. pmc 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer
    Guosheng Huang
    Department of Pathology, Division of Hematology Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio 44106, USA
    Cancer Res 68:5040-8. 2008
    ..In summary, we identify 15-PGDH as a direct downstream effector of HNF3beta and show that 15-PGDH acts as a tumor suppressor in lung cancer...
  19. ncbi Prostaglandin expression profile in hypoxic osteoblastic cells
    Christina M Lee
    Department of Anatomy, Physiology and Cell Biology, School of Veterinary Medicine, University of California Davis, 1321 Haring Hall, One Shields Ave, Davis, CA 95616, USA
    J Bone Miner Metab 28:8-16. 2010
    ..Previous studies have detected release of prostaglandins from areas of damaged bone, such as a fracture site, and our data may contribute to an understanding of how this release is regulated...
  20. ncbi Transactivation activity of human papillomavirus type 16 E6*I on aldo-keto reductase genes enhances chemoresistance in cervical cancer cells
    Panata Wanichwatanadecha
    Department of Biochemistry, Faculty of Science, Mahidol University, Rama VI Road, Bangkok 10400, Thailand
    J Gen Virol 93:1081-92. 2012
    ..Taken together, it was concluded that 16E6*I has a novel function in upregulating expression of AKR1C and, in concert with E7, has implications for drug treatment in HPV-mediated cervical cancer...
  21. ncbi Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation
    Heather R Roberts
    School of Cellular and Molecular Medicine, Cancer Research UK Colorectal Tumour Biology Research Group, University of Bristol, Bristol, BS8 1TD, UK
    Carcinogenesis 32:1741-7. 2011
    ....
  22. ncbi Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues
    Kamalesh K Sharma
    Department of Obstetrics Gynecology and Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Mol Cell Endocrinol 248:79-86. 2006
    ..Our findings suggest that AKR1C3 protects the mineralocorticoid receptor from activation by DOC in mineralocorticoid target cells of the kidney and colon, analogous to cortisol inactivation by 11beta-hydroxysteroid dehydrogenase type 2...
  23. pmc Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships
    Adegoke O Adeniji
    Department of Pharmacology and Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 6084, USA
    J Med Chem 55:2311-23. 2012
    ..Lead compounds did not inhibit COX-1 or COX-2 but blocked the AKR1C3 mediated production of testosterone in LNCaP-AKR1C3 cells. These compounds offer promising leads toward new therapeutics for CRPC...
  24. pmc Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2alpha synthase
    Ko Fujimori
    Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences, 4 20 1 Nasahara, Takatsuki, Osaka 569 1094, Japan
    J Biol Chem 285:8880-6. 2010
    ..These results indicate that AKR1B3 acts as the PGFS in adipocytes and that AKR1B3-produced PGF(2alpha) suppressed adipocyte differentiation by acting through FP receptors...
  25. pmc Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia
    Farhat L Khanim
    School of Biosciences, University of Birmingham, Birmingham, United Kingdom
    PLoS ONE 4:e8147. 2009
    ..In particular, therapies that have anti-leukaemic activity but that, unlike conventional chemotherapy, do not impair normal haemopoiesis...
  26. ncbi Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3
    Romana Novotna
    Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, CZ 50005 Hradec Kralove, Czech Republic
    Toxicol Lett 181:1-6. 2008
    ....
  27. pmc 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors
    Min Yan
    Department of Medicine and Pathology, Ireland Cancer Center, Case Western Reserve University and Case Medical Center, Cleveland, OH 44106, USA
    Proc Natl Acad Sci U S A 106:9409-13. 2009
    ..Specifically, in a colon adenoma prevention trial, in all cases tested, individuals who developed new adenomas while receiving celecoxib treatment were also found as having low colonic 15-PGDH levels...
  28. ncbi 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer
    Alexandra Thiel
    Department of Pathology, HUSLAB and Genome ScaleBiology Research Program, University of Helsinki, Helsinki, Finland
    Clin Cancer Res 15:4572-80. 2009
    ..We have investigated the expression and regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in gastric cancer...
  29. pmc Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis
    James J Lee
    Gastroenterology Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Carcinogenesis 31:427-34. 2010
    ..Thus, PTGES is a novel HIF-1alpha target gene, involved in prostaglandin E biosynthesis in the esophageal tumor hypoxic microenvironment, and this has implications in diverse tumors types, especially of squamous origin...
  30. ncbi Prostaglandin catabolizing enzymes
    Hsin Hsiung Tai
    Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington 40536 0082, USA
    Prostaglandins Other Lipid Mediat 68:483-93. 2002
    ..Future investigation may shed more light on the roles of these enzymes in health and diseases...
  31. pmc Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer
    Michael C Byrns
    Centers of Excellence in Environmental Toxicology and Cancer Pharmacology, Department of Pharmacology, University of Pennsylvania School of Medicine, 130C John Morgan Bldg, 3620 Hamilton Walk, Philadelphia, PA 19104 6084, United States
    J Steroid Biochem Mol Biol 118:177-87. 2010
    ....
  32. pmc 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers
    Min Yan
    Department of Medicine, Case Western Reserve University and University Hospitals, Cleveland, OH 44106, USA
    Proc Natl Acad Sci U S A 101:17468-73. 2004
    ..These findings thus delineate an enzymatic pathway that induces colon cancer suppression, a pathway that is activated by TGF-beta and mediated by 15-PGDH...
  33. ncbi Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer
    Evgeniy Eruslanov
    Department of Urology and Shands Cancer Center, University of Florida, College of Medicine, Gainesville, FL 32610, USA
    J Immunol 182:7548-57. 2009
    ..This study for the first time demonstrates an important role of the 15-PGDH in regulation of local antitumor immune response and highlights the potential to be implemented to enhance the efficacy of cancer therapy and immunotherapy...
  34. ncbi Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate
    Hsueh Kung Lin
    Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19018, USA
    Steroids 69:795-801. 2004
    ..The reagent thus has utility to access the localized expression of AKR1C3 in hormonal dependent malignancies of the breast and prostate...
  35. ncbi NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions
    H H Tai
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, 40536 0082, USA
    Curr Pharm Des 12:955-62. 2006
    ..Future investigations in these areas are warranted...
  36. pmc 15-oxo-Eicosatetraenoic acid, a metabolite of macrophage 15-hydroxyprostaglandin dehydrogenase that inhibits endothelial cell proliferation
    Cong Wei
    Center for Cancer Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6160, USA
    Mol Pharmacol 76:516-25. 2009
    ..This is the first report describing the biosynthesis of 15-oxo-ETE by macrophage/monocytes and its ability to inhibit endothelial cell proliferation...
  37. ncbi HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells
    Amy E Moore
    Cancer Research UK Colorectal Tumour Biology Group, Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, University Walk, Bristol, UK
    Carcinogenesis 30:1796-804. 2009
    ..Targeting the crosstalk between these two important pathways may be useful for therapeutic treatment of colorectal cancer...
  38. ncbi Reduction of 15-hydroxyprostaglandin dehydrogenase expression is an independent predictor of poor survival associated with enhanced cell proliferation in gastric adenocarcinoma
    Hiroshi Tatsuwaki
    Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan
    Cancer Sci 101:550-8. 2010
    ..These findings suggest that reduction of 15-PGDH is an independent predictor of poor survival associated with enhancement of cell proliferation in gastric adenocarcinoma...
  39. ncbi The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase
    Teruhisa Nomura
    Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Mol Pharmacol 65:973-8. 2004
    ..Our data represent reconstitution of the longstanding model of PG metabolism consisting of sequential carrier-mediated PG uptake, cytoplasmic oxidation, and diffusional efflux of the PG metabolite...
  40. ncbi Polymorphisms in fatty-acid-metabolism-related genes are associated with colorectal cancer risk
    Birgit Hoeft
    German Cancer Research Center, Heidelberg, Germany
    Carcinogenesis 31:466-72. 2010
    ..Our results support the key role of prostanoid signaling in colon carcinogenesis and suggest a relevance of genetic variation in fatty acid metabolism-related genes and CRC risk...
  41. ncbi 15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma
    Julio E Celis
    Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Mol Cell Proteomics 7:1795-809. 2008
    ....
  42. ncbi Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells
    Martina Gavelová
    Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, CZ 500 05 Hradec Kralove, Czech Republic
    Chem Biol Interact 176:9-18. 2008
    ..Taken together, the present results seem to suggest that the accelerated metabolic deactivation of ORC or DOX might contribute to the survival of breast cancer cells during exposure to these cytostatics...
  43. ncbi Crystal structure of human prostaglandin F synthase (AKR1C3)
    Junichi Komoto
    Department of Molecular Biosciences, University of Kansas, 1200 Sunnyside Avenue, Lawrence, Kansas 66045 7534, USA
    Biochemistry 43:2188-98. 2004
    ..Since the substrate binding cavity of PGFS is relatively large in comparison with those of AKR1C1 and AKR1C2, PGFS (AKR1C3) could catalyze the reduction and/or oxidation reactions of various compounds over a relatively wide pH range...
  44. pmc Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer
    Michael G Backlund
    Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Cancer Res 68:9331-7. 2008
    ..These results also provide a cyclooxygenase-2-independent mechanism to explain increased PGE(2) levels that contribute to progression of CRC...
  45. ncbi Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily
    Stephan Steckelbroeck
    Department of Pharmacology, University of Pennsylvania School of Medicine, 130C John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104 6084, USA
    J Pharmacol Exp Ther 316:1300-9. 2006
    ..The low hepatic formation of 3alpha-hydroxytibolone suggests that AKR1C4 is not the primary source of this metabolite and instead it maybe formed by an intestinal or enterobacterial 3alpha-HSD...
  46. ncbi Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha
    Taisuke Otani
    Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Am J Physiol Gastrointest Liver Physiol 290:G361-8. 2006
    ..The decrease in amounts of 15-PGDH in inflamed mucosa can be explained at least, in part, by TNF-alpha-mediated suppression of 15-PGDH transcription...
  47. ncbi Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity
    K Matsuura
    Laboratory of Biochemistry, Gifu Pharmaceutical University, Gifu, 502 8585, Japan
    J Biochem 124:940-6. 1998
    ..These results suggest that AKR1C3 acts as prostaglandin D2 11-ketoreductase, and that its principal gene in the human has a coding region represented by DBDH cDNA...
  48. pmc Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3)
    Adegoke O Adeniji
    Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104 6084, USA
    Bioorg Med Chem Lett 21:1464-8. 2011
    ..These compounds may be useful in treatment and/or prevention of CRPC as well as understanding the role of AKR1C3 in endocrinology...
  49. ncbi Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells
    Min Tong
    Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536 0082, USA
    Endocrinology 145:2141-7. 2004
    ..These results indicate that the induction of 15-PGDH by DHT, IL-6, and forskolin in LNCaP cells may involve a functional androgen receptor and phosphorylation-dependent multiple signaling pathways...
  50. pmc 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer
    Hsin Hsiung Tai
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 0082, USA
    Prostaglandins Other Lipid Mediat 83:203-8. 2007
    ..These results suggest that tumor suppressive action of these agents may, in part, be related to their ability to induce 15-PGDH expression...
  51. ncbi 15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells
    Min Tong
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 0082, USA
    Arch Biochem Biophys 435:50-5. 2005
    ..The induction of 15-PGDH expression by dexamethasone and other glucocorticoids at the therapeutic level provides an additional biochemical mechanism for the anti-inflammatory action of these glucocorticoids...
  52. ncbi Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis
    Satoshi Endo
    Laboratory of Biochemistry, Gifu Pharmaceutical University, Gifu 501 1196, Japan
    J Nat Prod 75:716-21. 2012
    ..Additionally, 1 suppressed the proliferation of PC3 prostatic cancer cells stimulated by AKR1C3 overexpression. This study is the first demonstration that 1 is a highly selective inhibitor of AKR1C3...
  53. ncbi 3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3
    Stephen M F Jamieson
    Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
    J Med Chem 55:7746-58. 2012
    ....
  54. pmc Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library
    Petra Brozic
    Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
    J Med Chem 55:7417-24. 2012
    ..Two of the best selective AKR1C3 inhibitors had K(i) values of 0.1 and 2.7 μM, exceeding expected activity for fragments. The compounds identified represent an excellent starting point for further hit-to-lead development...
  55. pmc N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3
    Maša Sinreih
    Institute of Biochemistry, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
    Bioorg Med Chem Lett 22:5948-51. 2012
    ..In addition, five selective inhibitors of AKR1C3 were identified. The most promising inhibitors were compounds 10 and 13, with IC(50) values of 0.31 μM and 0.35 μM for AKR1C3, respectively...
  56. ncbi Indomethacin increases 15-PGDH mRNA expression in HL60 cells differentiated by PMA
    M Frenkian
    INSERM Unit 349, Centre Viggo Petersen, , , Paris Cedex 10, 75475, France
    Prostaglandins Leukot Essent Fatty Acids 64:87-93. 2001
    ..Indomethacin, in association with PMA can consequently exert a dual control on key enzymes of PGE2 metabolism without modifying adhesion of the cells...
  57. ncbi Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival
    YARI E MARIN
    The Johnson and Johnson Skin Research Center, CPPW, a Unit of Johnson and Johnson Consumer Companies Inc, Skillman, NJ 08558, USA
    Exp Dermatol 18:611-8. 2009
    ....
  58. ncbi Genomic structure and transcriptional regulation of the human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene
    A Nandy
    IHF Institute for Hormone and Fertility Research, University of Hamburg, Falkenried 88, 20251 Hamburg, Germany
    J Mol Endocrinol 31:105-21. 2003
    ..CREB activated the PGDH-DE construct through the CREB1 site. These results defined the distal element as an integrator of transcriptional regulation by AP-1, Ets and CREB proteins...
  59. ncbi AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids
    Lucie Skarydová
    Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic
    Chem Biol Interact 178:138-44. 2009
    ..Moreover, since the inhibition is selective towards AKR1C3, 2'-hydroxyflavanone could be useful for treating or preventing hormone-dependent malignancies like prostate and breast cancer...
  60. ncbi Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase
    Virginie Quidville
    Institut National de la Santé et de la Recherche Médicale Unité 349, Hopital Lariboisiere, Centre Viggo Petersen, 2 rue Ambroise Pare, 75475 Paris Cedex 10, France
    Endocrinology 145:2561-71. 2004
    ..The synthesis enzyme, COX-1, and the catabolism enzyme 15-prostaglandin dehydrogenase, could be involved in MTC development...
  61. ncbi Mechanical stress and prostaglandin E2 synthesis in cartilage
    Marjolaine Gosset
    Physiology and Physiopathology Laboratory, Paris Universitas UPMC Paris VI and CNRS UMR 7079, 75252 Paris, Cedex 5, France
    Biorheology 45:301-20. 2008
    ..Notably, compression increases mPGES-1 mRNA and protein expression in cartilage explants. Thus, the mechanosensitive mPGES-1 enzyme represents a potential therapeutic target in osteoarthritis...
  62. pmc Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3
    Jack U Flanagan
    Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
    PLoS ONE 7:e43965. 2012
    ..This new data from ten crystal structures greatly broadens the base of structures available for future structure-guided drug discovery efforts...
  63. pmc Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights
    Michael C Byrns
    Center of Excellence in Environmental Toxicology, Department of Pharmacology, University of Pennsylvania School of Medicine, 130C John Morgan Bldg, 3620 Hamilton Walk, Philadelphia, PA 19104 6084, United States
    J Steroid Biochem Mol Biol 125:95-104. 2011
    ..These pockets can be used to further improve the binding affinity and selectivity of the currently available AKR1C3 inhibitors. Article from the special issue on Targeted Inhibitors...
  64. ncbi NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer
    Yunfei Ding
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, USA
    Carcinogenesis 26:65-72. 2005
    ..Furthermore, the expression of 15-PGDH was found to be stimulated by hyaluronidase. These results suggest that 15-PGDH may decrease the level of proliferative PGE2, induce apoptosis and function like a tumor suppressor...
  65. ncbi Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma
    K M Fung
    Department of Urology, University of Oklahoma Health Sciences Center, 920 Stanton L Young Blvd, WP3150, Oklahoma City, OK 73104, USA
    Endocr Relat Cancer 13:169-80. 2006
    ..Although the biological significance of elevated AKR1C3 in prostatic carcinoma is uncertain, AKR1C3 may be responsible for the trophic effects of androgens and/or PGs on prostatic epithelial cells...
  66. ncbi Prostaglandin F synthase
    Kikuko Watanabe
    Division of Applied Life Sciences, Graduate School of Integrated Sciences and Arts, University of East Asia, Shimonoseki, Yamaguchi, Japan
    Prostaglandins Other Lipid Mediat 68:401-7. 2002
    ..Here, these three pathways of PGF synthesis by these enzymes are reviewed, and the physiological roles of the enzymes are discussed...
  67. ncbi Prostaglandin F(2alpha) suppresses early phase of adipogenesis, but is not associated with osteoblastogenesis in mouse mesenchymal stem cells
    Ko Fujimori
    Laboratory of Biodefense and Regulation, Osaka University of Pharmaceutical Sciences, 4 20 1 Nasahara, Takatsuki, Osaka 569 1094, Japan
    Prostaglandins Other Lipid Mediat 93:52-9. 2010
    ..Therefore, PGF(2alpha) suppressed the progression of early phase adipogenesis after determination of the cell fate that causes MSC to differentiate into adipocytes...
  68. pmc Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma
    Vladislav Zakharov
    Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
    Int J Clin Exp Pathol 3:608-17. 2010
    ..However, reduced AKR1C3 expression cannot distinguish hyperplastic endometrium from endometrial adenocarcinoma of endometrial type. The biologic and pathological roles of AKR1C3 in endometrial epithelium require further investigation...
  69. ncbi Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost
    Junichi Komoto
    Department of Molecular Biosciences, University of Kansas, 1200 Sunnyside Avenue, Lawrence, Kansas 66045 7534, USA
    Biochemistry 45:1987-96. 2006
    ..Formation of PGF(2)(alpha) from PGH(2) most likely involves a direct hydride transfer from the bound NADPH to the endoperoxide of PGH(2) without the participation of specific amino acid residues...
  70. pmc An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone indepe
    Michael C Byrns
    Center for Excellence in Environmental Toxicology, Department of Pharmacology, University of Pennsylvania School of Medicine, 3620 Hamilton Walk, Philadelphia, PA 19104 6084, United States
    Biochem Pharmacol 75:484-93. 2008
    ..The identification of CBM as a specific inhibitor of AKR1C3 will aid the investigation of its roles in steroid hormone and prostaglandin signaling and the resultant effects on cancer development...
  71. ncbi Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance
    Zachary W Veitch
    Department of Biology, Laurentian University, Northern Ontario School of Medicine, Sudbury, Canada
    Pharmacogenet Genomics 19:477-88. 2009
    ....
  72. ncbi Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues
    Wei Qiu
    Oncology and Molecular Endocrinology Research Center, Centre Hospitalier de l Université Laval Medical Center CHUL and Laval University, Sainte Foy, Quebec, Canada G1V 4G2
    Mol Endocrinol 18:1798-807. 2004
    ..These structures have provided a dynamic view of the enzyme reaction converting androstenedione to testosterone as well as valuable information for the development of potent enzyme inhibitors...
  73. ncbi AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer
    Tea Lanisnik Rizner
    Institute of Biochemistry, Medical Faculty, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia
    Mol Cell Endocrinol 248:126-35. 2006
    ..It is suggested that the expression of AKR1C1 and AKR1C3 in endometrial cancer will govern the ratio of P:E2...
  74. ncbi Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells
    Min Tong
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky Lexington, KY 40536 0082, USA
    Carcinogenesis 27:2170-9. 2006
    ..The levels of IL-1beta-induced COX-2 expression appeared to correlate inversely with those of 15-PGDH expression in the cells. These results support the contention that COX-2 and 15-PGDH are regulated reciprocally in A549 cells...
  75. ncbi The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis
    Jane Birtwistle
    School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    Mutat Res 662:67-74. 2009
    ....
  76. ncbi 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line
    Virginie Quidville
    Institut National de la Santé et de la Recherche Médicale U 606, Paris 75010, France
    Prostaglandins Other Lipid Mediat 81:14-30. 2006
    ..NSAIDs defined by their COX inhibition should also be defined by their effect on 15-PGDH...
  77. ncbi The effect of ovarian steroids on oxytocin-stimulated secretion and synthesis of prostaglandins in bovine myometrial cells
    Dominika Slonina
    Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, 10 747 Olsztyn, Poland
    Prostaglandins Other Lipid Mediat 90:69-75. 2009
    ....
  78. pmc Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system
    Joseph Azzarello
    Department of Urology, University of Oklahoma Health Sciences Center, 800 Research Parkway, Room 462, Oklahoma City, OK 73034, USA
    J Histochem Cytochem 56:853-61. 2008
    ..These features warrant future studies of AKR1C3 in both hormone- and non-hormone-associated tissues and identification of the rodent homolog for establishing animal models...
  79. ncbi AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells
    Shaobin Wang
    Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States
    Mol Cell Endocrinol 289:60-6. 2008
    ..Our results suggested that both AKR1C2 and AKR1C3 mediate similar PGD2 conversion toward the accumulation of proliferative signals through FP and PI3K/Akt signaling pathways to promote prostate cell proliferation...
  80. ncbi Structural basis of the multispecificity demonstrated by 17beta-hydroxysteroid dehydrogenase types 1 and 5
    S X Lin
    Molecular Endocrinology Research Center at Laval University Hospital Research Center CHUL, CHUQ, Laval University, Que, Canada G1V 4G2
    Mol Cell Endocrinol 248:38-46. 2006
    ..The multi-specificity contributes significantly to steroid metabolism in peripheral tissues, due to the high levels of 17beta-HSD5 mRNA in both breast and prostate tissues...
  81. ncbi Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas
    Nam Jin Yoo
    Pathology 39:174-5. 2007
  82. ncbi C-Terminal region of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase is involved in the interaction with prostaglandin substrates
    H Zhou
    Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 0082, USA
    Eur J Biochem 268:3368-74. 2001
    ..The C-terminal region appears to be more important for the interaction of the enzyme with the prostaglandin substrates than with the coenzyme...
  83. ncbi Purification and structural characterization of placental NAD(+)-linked 15-hydroxyprostaglandin dehydrogenase. The primary structure reveals the enzyme to belong to the short-chain alcohol dehydrogenase family
    M Krook
    Department of Chemistry I, Karolinska Institutet, Stockholm, Sweden
    Biochemistry 29:738-43. 1990
    ..The protein has four cysteine residues (five with the positional microheterogeneity), but there is no evidence for functional importance of any of these residues.(ABSTRACT TRUNCATED AT 250 WORDS)..
  84. ncbi Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents
    H Cho
    Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 0082, USA
    Prostaglandins Leukot Essent Fatty Acids 67:461-5. 2002
    ..Among these compounds, ciglitazone appeared to be the most powerful inhibitor (IC(50)=2.7 microM). Inhibition by ciglitazone was non-competitive with respect to NAD(+) and uncompetitive with respect to PGE(2)...
  85. ncbi Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin
    Andrew L Lovering
    The School of Biosciences, The University of Birmingham, Birmingham, United Kingdom
    Cancer Res 64:1802-10. 2004
    ..The data underline AKR1C3 as a COX-independent target for NSAID and will provide a structural basis for the future development of new cancer therapies with reduced COX-dependent side effects...
  86. ncbi Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder
    Jason R Gee
    Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Urol Oncol 21:266-70. 2003
    ..CK20, AN43 and PGDH decreased but COX-2 expression increased in higher stage tumors. The histologic phenotype of these cancers is reflected in their expression of these proteins and is modified further as tumors progress in stage...
  87. ncbi Key NAD+-binding residues in human 15-hydroxyprostaglandin dehydrogenase
    Hoon Cho
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 0082, USA
    Arch Biochem Biophys 433:447-53. 2005
    ..These results suggest that Ile-17, Asn-91, and Val-186 are involved in the interaction with NAD(+) and contribute to the full catalytic activity of 15-PGDH...
  88. pmc Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma
    Michael J Lewis
    Department of Biology University of Western Ontario, London, Canada
    BMC Cancer 4:27. 2004
    ..The aim of this study was to determine if the differences in enzyme activities between tumorous and nontumorous breast tissues are associated with differences in progesterone metabolizing enzyme gene expression...
  89. ncbi Thiazolidinediones as a novel class of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors
    Hoon Cho
    Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536 0082, USA
    Arch Biochem Biophys 405:247-51. 2002
    ..This regulatory site appears to overlap with the activator site occupied by imipramine since activation of the enzyme by this activator is competitively inhibited by compound CT-8...
  90. ncbi Cloning and sequence analysis of the cDNA for human placental NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase
    C M Ensor
    Division of Medicinal Chemistry and Pharmaceutics, College of Pharmacy, University of Kentucky, Lexington 40536 0082
    J Biol Chem 265:14888-91. 1990
    ..4 kilobases and the other of 2.0 kilobases. Isolation of the cDNA for 15-hydroxyprostaglandin dehydrogenase should facilitate studies on the structure, function, and regulation of this enzyme...
  91. ncbi The human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase gene promoter is controlled by Ets and activating protein-1 transcription factors and progesterone
    K J Greenland
    IHF Institute for Hormone and Fertility Research, University of Hamburg, Germany
    Endocrinology 141:581-97. 2000
    ....
  92. ncbi Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression
    Jason R Mann
    Departments of Cell and Developmental Biology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 2300 Pierce Avenue, Nashville, TN 37232, USA
    Cancer Res 66:6649-56. 2006
    ..These data indicate that PGDH may serve a tumor suppressor function in colorectal cancer and provide a possible COX-2-independent way to target PGE(2) to inhibit cancer progression...
  93. ncbi Cytokine-induced coordinate expression of enzymes of prostaglandin biosynthesis and metabolism: 15-hydroxyprostaglandin dehydrogenase
    M D Mitchell
    Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The University of Auckland, New Zealand
    Prostaglandins Leukot Essent Fatty Acids 62:1-5. 2000
    ....
  94. pmc Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells
    Saswati Hazra
    Lung Cancer Research Program of the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Prostaglandins Leukot Essent Fatty Acids 77:51-8. 2007
    ..Here, we report that ciglitazone downregulates PGE2 in NSCLC cells...
  95. pmc Episode-specific differential gene expression of peripheral blood mononuclear cells in rapid cycling supports novel treatment approaches
    Martin Begemann
    Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Gottingen, Germany
    Mol Med 14:546-52. 2008
    ..This case suggests that rapid cycling is a systemic disease, resembling hibernation, with prostaglandins playing a mediator role...
  96. pmc Estrogen and progesterone metabolism in the cervix during pregnancy and parturition
    Stefan Andersson
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390 9032, USA
    J Clin Endocrinol Metab 93:2366-74. 2008
    ..Mice deficient in 5alpha-reductase type I fail to undergo cervical ripening at term despite the timely onset of luteolysis and progesterone withdrawal in blood...
  97. pmc Loss of prostaglandin E2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders
    Prerna Rastogi
    Department of Pathology, Saint Louis University School of Medicine, Doisy Research Bldg, 3rd Floor, 1110 S Grand Blvd, St Louis, MO 63104, USA
    Am J Physiol Renal Physiol 294:F1129-35. 2008
    ..Since PGE(2) is a cytoprotective eicosanoid, the failure to produce this metabolite in cells isolated from the IC bladder may represent an increased susceptibility to damage by proinfammatory stimuli...
  98. ncbi Coordinate regulation of prostaglandin metabolism for induction of parturition in mice
    Sandra K Winchester
    Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Endocrinology 143:2593-8. 2002
    ....
  99. ncbi Oxytocin stimulates prostaglandin F2alpha secretion and prostaglandin F synthase protein expression in porcine myometrial tissue
    Anita Franczak
    Department of Animal Physiology, Faculty of Biology, University of Warmia and Mazury in Olsztyn, Poland
    Reprod Biol 4:177-84. 2004
    ..In addition, OT increased PGD(2) 11-ketoreductase protein expression in myometrium harvested during the porcine estrous cycle. However, the OT-stimulated PGF(2)alpha myometrial secretion was observed in both, cycling and pregnant gilts...
  100. ncbi Differential expression of prostaglandin (PG) synthesis enzymes in conceptus during peri-implantation period and endometrial expression of carbonyl reductase/PG 9-ketoreductase in the pig
    Agnieszka Waclawik
    Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima 10, 10 747 Olsztyn, Poland
    J Endocrinol 194:499-510. 2007
    ..Moreover, high expression of conceptus PGHS-1, mPGES-1, PGFS, and CBR1 after initiation of implantation suggests their significant role in placentation...
  101. pmc Preterm birth without progesterone withdrawal in 15-hydroxyprostaglandin dehydrogenase hypomorphic mice
    Jeffrey D Roizen
    Washington University School of Medicine, St Louis, Missouri 63110, USA
    Mol Endocrinol 22:105-12. 2008
    ..Thus, endocrine control of labor has the capacity to plastically adapt to changes in genetically determined prostaglandin signals...

Research Grants20

  1. Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention
    JOHN JAMES LETTERIO; Fiscal Year: 2013
    ..The observations outlined above are the basis for our hypothesis that colon cancer chemoprevention by triterpenoids requires a TGF-b-dependent induction of 15- PGDH. ..
  2. Role of PGDH in leukemia pathogenesis
    Michael L Cleary; Fiscal Year: 2013
    ....
  3. INHIBITION OF 3A HSD BY ANTI-INFLAMMATORY DRUGS
    TREVOR PENNING; Fiscal Year: 1991
    ..These studies may provide information for a rational approach to the design of superior antiinflammatory drugs...
  4. MECHANISMS FOR CHEMOPREVENTION OF COLORECTAL CANCER
    Michael Backlund; Fiscal Year: 2007
    ..It is becoming increasing apparent that the targeting of a single molecule will not be as effective as is needed to have a significant impact on this disease. [unreadable] [unreadable] [unreadable]..
  5. CHEMISTRY OF FOLATE AND PTERIDINE COENZYMES
    JOHN WHITELEY; Fiscal Year: 2000
    ..coli, purified to homogeneity, and crystallized in its apo- and ATP-bound form. Structural characterization of these complexes may contribute to the understanding of how drug efflux pumps function. ..
  6. Genetic Study of Prostaglandin Synthesis/EGFR and Risk of Colorectal Neoplasia
    Cornelia Ulrich; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  7. ENZYMES IN PROSTAGLANDIN METABOLISM
    Hsin Hsiung Tai; Fiscal Year: 1980
    The proposed research project aims at studying four different types of 15-hydroxyprostaglandin dehydrogenases and two types of ketoprostaglandin reductases...
  8. ENZYMES IN EICOSANOID METABOLISM
    Hsin Hsiung Tai; Fiscal Year: 2004
    ..Furthermore, the program should uncover novel properties of 5-HEDH and shed some light on the role of this enzyme in the inflammatory and allergic reactions. ..
  9. Polarized DC as Melanoma Vaccine: Phase 1 Evaluation
    Pawel Kalinski; Fiscal Year: 2006
    ....
  10. Regulation of DC Activity by Memory and Effector CD8+ T Cells
    Pawel Kalinski; Fiscal Year: 2010
    ..abstract_text> ..
  11. Halogenated Alkenes and Microsomal GSH-transferases
    Michael J Kelner; Fiscal Year: 2010
    ..4] To determine the relative contribution of MGST1 and MGST2 to cellular antioxidant capacity through studies utilizing human MGST1 and MGST2 null cells. ..
  12. COX-2 Inhibitors, APC and Colon Cancer Prevention
    Kotha Subbaramaiah; Fiscal Year: 2009
    ..These studies will enhance our understanding of the mechanistic link between COX-2 and colorectal cancer and potentially assist us in optimizing the use of selective COX-2 inhibitors as therapy. ..
  13. Molecular Mechanisms of Multistage Carcinogenesis
    TREVOR PENNING; Fiscal Year: 2006
    ..By studying the discrete molecular events responsible for the causation of cancer this Program may lead to the early prevention and intervention of this disease. ..
  14. Genetic Polymorphisms Benign Prostatic Hyperplasia
    ROSEBUD ROBERTS; Fiscal Year: 2004
    ..This community-based cohort study should provide insights that should improve our understanding of the genetic control of hormonal mechanisms in the pathogenesis of BPH. ..
  15. Vascular and Inflammatory Predictors of MCI Risk and Progression
    ROSEBUD ROBERTS; Fiscal Year: 2008
    ..The K01 award will culminate in an R01 application that will pave the way for the candidate to become an independent investigator in MCI and AD research. [unreadable] [unreadable] [unreadable]..
  16. PROSTAGLANDINS IN PRIMATE OVULATORY FOLLICLES
    DIANE DUFFY; Fiscal Year: 2003
    ..This may provide insight into the mechanisms leading to infertility (e.g., leuteinized unruptured follice syndrome) and support the developoment of PG synthesis inhibitors of PG synthesis inhibitors for use as contraceptives. ..
  17. Symposium on Aldo-Keto Reductases & Toxicant Metabolism
    TREVOR PENNING; Fiscal Year: 2002
    ..abstract_text> ..
  18. GPX1 ENZYME REGULATION BY OXIDATIVE XENOBIOTICS
    Michael Kelner; Fiscal Year: 2002
    ..These studies will provide critical information regarding cellular response to oxidative stress and aid in determining if a common regulatory mechanism exists for GSH-dependent enzymes. ..
  19. COORDINATED REGULATION OF ANTIOXIDANT ENZYMES
    Michael Kelner; Fiscal Year: 2005
    ..abstract_text> ..